neuromyelitis optica spectrum disorder
Neurology · 2020–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ravulizumab Treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are aquaporin-4 (AQP4) antibody positive, who have experienced a recent… | Nov 2024 | Recommended with restriction | 3 individuals |
| eculizumab Treatment of patients with neuromyelitis optica spectrum disorder (NMOSD) who are aquaporin-4 positive (AQP4+) with an Expanded Disability Status Scale (EDSS)… | Nov 2021 | Not recommended | input received MS Australia |
| eculizumab Treatment of patients with neuromyelitis optica spectrum disorder (NMOSD) who are aquaporin-4 (AQP4) positive and who have either frequent relapses or a prior… | Nov 2020 | Not recommended | input received MS Australia · MS Research Australia |
Who spoke
MS Australia · MS Research Australia
What the PBS pays
$143M in government benefit over 2024–25, across 2,593 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ravulizumab | $105.7M |
| eculizumab | $37.1M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 0 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| inebilizumabUPLIZNA inebilizumab 100 mg/10 mL concentrated injection vial | 2025 | 1 |
| satralizumabENSPRYNG satralizumab 120 mg/1 mL solution for injection in pre-filled | 2020 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.